Technical Analysis for NVNO - enVVeno Medical Corporation

Grade Last Price % Change Price Change
D 5.10 0.79% 0.04
NVNO closed up 0.79 percent on Wednesday, May 8, 2024, on 13 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.79%
20 DMA Support Bullish 0.79%
Bollinger Band Squeeze Range Contraction 0.79%
Earnings Movers Other 0.79%
Crossed Above 20 DMA Bullish 0.20%
Bollinger Band Squeeze Range Contraction 0.20%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 5 hours ago
Possible Inside Day about 5 hours ago
10 DMA Resistance about 8 hours ago
60 Minute Opening Range Breakout about 8 hours ago
Rose Above 10 DMA about 8 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

enVVeno Medical Corporation Description

enVVeno Medical is an Irvine, California based medical device company focused on the development of innovative bioprosthetic (tissue-based) solutions to improve the standard of care in the treatment of venous disease. The Company's lead product, the VenoValveĀ®, is a first-in-class implant being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). In healthy patients, valves inside the veins of the leg assist in propelling blood up the leg, and back to the heart and lungs. Affecting approximately 2.4 million people in the United States, CVI occurs when valves inside of the veins of the leg become damaged, resulting in the backwards flow of blood (reflux), blood pooling in the lower leg, increased pressure in the veins of the leg (venous hypertension) and in severe cases, venous ulcers that are difficult to heal and become chronic. Implanted into the femoral vein, the VenoValve is designed to act as a one-way valve, to help restore proper blood flow in the leg. The VenoValve is currently being evaluated in the SAVVE pivotal study with data expected in late 2022.


Classification

Sector: Healthcare
Industry: Medical Devices
Keywords: Vascular Disease Ulcer Veins Circulatory System Angiology Cardiovascular System Chronic Venous Insufficiency Insufficiency Venous Insufficiency Venous Ulcer

Is NVNO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 6.97
52 Week Low 2.51
Average Volume 113,175
200-Day Moving Average 4.92
50-Day Moving Average 5.48
20-Day Moving Average 5.05
10-Day Moving Average 5.14
Average True Range 0.28
RSI (14) 47.92
ADX 13.22
+DI 16.58
-DI 14.54
Chandelier Exit (Long, 3 ATRs) 4.75
Chandelier Exit (Short, 3 ATRs) 5.42
Upper Bollinger Bands 5.46
Lower Bollinger Band 4.64
Percent B (%b) 0.56
BandWidth 16.12
MACD Line -0.05
MACD Signal Line -0.07
MACD Histogram 0.018
Fundamentals Value
Market Cap 67.91 Million
Num Shares 13.3 Million
EPS -2.14
Price-to-Earnings (P/E) Ratio -2.38
Price-to-Sales 0.00
Price-to-Book 2.30
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.32
Resistance 3 (R3) 5.33 5.27 5.29
Resistance 2 (R2) 5.27 5.21 5.27 5.27
Resistance 1 (R1) 5.19 5.18 5.23 5.17 5.26
Pivot Point 5.12 5.12 5.14 5.12 5.12
Support 1 (S1) 5.04 5.07 5.08 5.03 4.94
Support 2 (S2) 4.97 5.03 4.97 4.93
Support 3 (S3) 4.89 4.97 4.91
Support 4 (S4) 4.88